Clinical benefit of R-CHOP without splenectomy in stage i primary splenic diffuse large B-cell lymphoma
Document Type
Article
Publication Title
BMJ Case Reports
Abstract
Primary splenic diffuse large B-cell lymphoma (PS-DLBCL) is a relatively rare malignancy, and there are no optimal approaches for diagnosis and management. There are less invasive splenic biopsies that effectively obviate diagnostic and elective splenectomies. We report a man in his 50s with 2-day history of pain in the abdomen and who was found to have a splenic mass on PET-CT. A CT-guided core needle splenic biopsy confirmed the diagnosis of PS-DLBCL. He was managed with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) alone, without splenectomy. The patient attained complete remission, and he is disease free at 6 years of follow-up.
DOI
10.1136/bcr-2021-246610
Publication Date
1-4-2022
Recommended Citation
Rajendran, Tara; Kini, Jyoti Ramanath; Abna, Aysha; and Prasad, Krishna, "Clinical benefit of R-CHOP without splenectomy in stage i primary splenic diffuse large B-cell lymphoma" (2022). Open Access archive. 4697.
https://impressions.manipal.edu/open-access-archive/4697
